Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib
2215-CL-0201
Phase 3 small_molecule active
Quick answer
Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib for Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy is a Phase 3 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active